NFE2 and acute myeloid leukemia: Patients not belonging to one of these two groups were classified according to their driver mutation either CALR and chr20q-, MPL with higher risk of AML transformation, homozygous JAK2 or NFE2 mutations with increased risk of MF transformation, or a heterozygous JAK2 mutation mostly with favorable outcome.